Search global stocks & ETFs...Ctrl K
Learn Mode
IBRX
Stock Profile
08-03
Recommended Metric
Score Card
Explore Scores Tab
2.64
Average
Valuation Score
Key Score
1.00
Very Bad
Management
4.00
Good
Growth
5.00
Very Good
Profitability
2.00
Bad
Fin. Health
1.00
Very Bad
Dividends
--
--
Analyst
2.00
Bad
Insider Transactions
Explore Insider Tab ›Buy Transactions
Sell Transactions
Peers
Select stocks to compare
Price Targets & Ratings
View Analysis
1-year price targets, ending May 11, 2027
Current
$9.20
Baseline
High
$23.10
▲
151.09%
Avg
$14.69
▲
59.65%
Low
$11.11
▲
20.76%
Analyst Ratings based on 10 Analysts
Strong Buy
440%
Buy
550%
Hold
110%
Sell
000%
Strong Sell
000%
ImmunityBio, Inc. is a clinical stage immunotherapy company. The company is headquartered in San Diego, California and currently employs 691 full-time employees. The company went IPO on 2015-07-28. Using its applied science and platforms to treat cancers, including the development of potential cancer vaccines, as well as developing immunotherapies and cell therapies to reduce or eliminate the need for standard high-dose chemotherapy. Its platforms and their associated product candidates are designed to attack cancer and infectious pathogens by activating both the innate immune system, including NK cells, dendritic cells, and macrophages, as well as the adaptive immune system comprising B and T cells, in an orchestrated manner. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins, vaccine vectors, and cell therapies. Its biologic commercial product candidate, Anktiva, is an IL-15 superagonist antibody-cytokine fusion protein.Read More
Stock News
View All Updates
News100%Bullish
Jim Cramer Calls CAVA 'Tasty, Clean, Fun,' Says Make This Biotech 'Your Speculation'
2wBenzinga
HC Wainwright & Co. Reiterates Buy on ImmunityBio, Maintains $15 Price Target
4wBenzinga
ImmunityBio Presents Data At American Society Of Clinical Oncology Annual Meeting About Its Phase 3 Studies In Advanced Non-Small Cell Lung Cancer
4wBenzinga
Undercovered Dozen: Cerebras Systems, Infleqtion, Duos Technologies And More
5wSeekingAlpha
ImmunityBio Announces Preliminary Results From News Economic Analysis Showing That Anktiva Plus Bacillus Calmette–Guérin Achieved A Lower Cost Per Sustained Complete Responder
5wBenzinga
ImmunityBio Announces New Survey Data Showing Diverse Treatment Preferences And Priorities Of Patients With Bacillus Calmette–Guérin-Unresponsive High-Risk Non-Muscle-Invasive Bladder Cancer
5wBenzinga
BTIG Reiterates Buy on ImmunityBio, Maintains $12 Price Target
6wBenzinga
ImmunityBio: Could Be One Approval Away From A Multi-Billion Dollar Breakout
6wSeekingAlpha
TAT Technologies Posts Upbeat Q1 Earnings, Joins Roivant Sciences, Immunitybio And Other Big Stocks Moving Higher On Wednesday
6wBenzinga
ImmunityBio Stock Climbs As FDA Accepts Expanded Use Filing For Bladder Cancer Drug
6wBenzinga
Reported Earlier, ImmunityBio Says FDA Accepted ANKTIVA Plus Bacillus Calmette-Guerin Filing For Papillary Non-Muscle Invasive Bladder Cancer Following Workshop Support And National Comprehensive Cancer Network Guidance
6wBenzinga
ImmunityBio Says ANKTIVA Combo Outperformed Rival Bladder Cancer Therapies
6wBenzinga
ImmunityBio: Looking Beyond Bladder Cancer To A Multibillion-Dollar Solid Tumor TAM
6wSeekingAlpha
ImmunityBio Announces Results From Two ITC Analyses Presented At 2026 AUA Annual Meeting Evaluating Nogapendekin Alfa inbakicept-pmln Plus BCG
6wBenzinga
ImmunityBio Expands Bladder Cancer Arsenal With Exclusive Japanese BCG Partnership
6wBenzinga
ImmunityBio Secures Five US Patents Covering Combination Of IL-15 Receptor Agonist ANKTIVA With Bacillus Calmette-Guérin For Treatment Of Cancer
6wBenzinga
ImmunityBio Announces Comprehensive U.S. Patents Covering Combination of ANKTIVA with BCG for Cancer Treatment, with Terms Through 2035
6wFinnhub
Reported Saturday, ImmunityBio Secures Exclusive US Rights To Tokyo-172 BCG After Phase 3 Trial Shows Non-Inferior Efficacy To TICE BCG
6wBenzinga
ImmunityBio Signs Exclusive U.S. Agreement with Japan BCG Laboratory for the Tokyo Strain of BCG to Enhance BCG Supply in the United States
6wFinnhub
IBRX 12-DAY DEADLINE ALERT: ImmunityBio (IBRX) Investors Face Losses Amid FDA Warning Regarding Unsupported Cancer Treatment Claims -- Hagens Berman
6wFinnhub
Berger Montague Reminds ImmunityBio, Inc. (IBRX) Investors of Class Action Lawsuit Deadline
6wFinnhub
ImmunityBio, Inc. (IBRX) Investors: May 26, 2026 Filing Deadline in Securities Class Action - Contact Lieff Cabraser
6wFinnhub
ImmunityBio, Inc. (IBRX) Investors with Substantial Losses Have Opportunity to Lead Investor Class Action Lawsuit - RGRD Law
7wFinnhub
IBRX INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Reminds ImmunityBio (IBRX) Investors of Securities Class Action Deadline on May 26, 2026
7wFinnhub
IBRX SHAREHOLDER RIGHTS ALERT: Faruqi & Faruqi, LLP Reminds ImmunityBio (IBRX) Investors of Securities Class Action Deadline on May 26, 2026
7wFinnhub
ImmunityBio, Inc. Securities Fraud Class Action Result of FDA Warning and 21% Stock Decline - Investors may Contact Lewis Kahn, Esq, at Kahn Swick & Foti, LLC
7wFinnhub
ImmunityBio Stock Drops After Earnings Miss Despite Anktiva Momentum
7wBenzinga
ImmunityBio Inc (NASDAQ:IBRX) Q1 Revenue Beat Overshadowed by Wider Losses and Stock Decline
7wChartMill
IBRX CLASS ACTION NOTICE: Faruqi & Faruqi, LLP Reminds ImmunityBio (IBRX) Investors of Securities Class Action Deadline on May 26, 2026
7wFinnhub
IBRX SHAREHOLDER UPDATE: ImmunityBio (IBRX) Sued After FDA Flags Misleading Cancer Claims, Shares Plunge 21%, $2B Market Cap Lost -- Hagens Berman
7wFinnhub
ImmunityBio, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026
7wFinnhub
UPDATE: ImmunityBio Q1 Adj. EPS $(0.08) Misses $(0.07) Estimate, Sales $44.206M Beat $43.069M Estimate
7wBenzinga
ImmunityBio Q1 EPS $(0.62) Misses $(0.07) Estimate, Sales $44.206M Beat $43.069M Estimate
7wBenzinga
IMMUNITYBIO, INC. SECURITIES FRAUD NOTICE: Berger Montague Informs ImmunityBio, Inc. (IBRX) Investors of a Securities Fraud Lawsuit
7wFinnhub
ImmunityBio: Q1 Earnings Snapshot
7wFinnhub
ImmunityBio Reports Record Q1 2026 Results: Net Product Revenue Increased Nearly 2.7x Year-Over-Year to $44 Million in Q1 2026 Expanding on the 2025 Full Year 700% Year-Over-Year Revenue Growth; Cash and Marketable Securities Total $381 Million
8wFinnhub
Why ImmunityBio Stock Is Surging On Wednesday?
8wBenzinga
ImmunityBio To Present New Treatment Comparison Results Evaluating ANKTIVA Plus BCG Versus Nadofaragene Firadenovec-Vncg And TAR-200 In Patients With NMIBC CIS, With Or Without Papillary Disease, At AUA 2026
8wBenzinga
ImmunityBio to Present New Comparative Data, Scientific Advances in Non-Muscle Invasive Bladder Cancer CIS and an Update on BCG Naïve Registrational Trial at American Urological Association Annual Meeting
8wFinnhub
IBRX INVESTOR NOTICE: Faruqi & Faruqi, LLP Reminds ImmunityBio (IBRX) Investors of Securities Class Action Deadline on May 26, 2026
8wFinnhub
IBRX DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds ImmunityBio (IBRX) Investors of Securities Class Action Deadline on May 26, 2026
9wFinnhub
IBRX SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Reminds ImmunityBio (IBRX) Investors of Securities Class Action Deadline on May 26, 2026
9wFinnhub
IBRX Faruqi & Faruqi, LLP Reminds ImmunityBio (IBRX) Investors of Securities Class Action Deadline on May 26, 2026
9wFinnhub
INVESTOR DEADLINE: ImmunityBio, Inc. (IBRX) Investors with Substantial Losses Have Opportunity to Lead the ImmunityBio Class Action Lawsuit- Hagens Berman
9wFinnhub
BUZZ Investing: April Rebound Calms A March Washout
9wSeekingAlpha
IBRX Berger Montague Advises ImmunityBio, Inc. (IBRX) Investors of a May 26, 2026 Deadline
10wFinnhub
Avis Brings Back The Short Squeeze — Navitas, Beyond Meat Join In
10wBenzinga
IMMUNITYBIO, INC. (IBRX) DEADLINE ALERT Bernstein Liebhard LLP Reminds ImmunityBio, Inc. Investors of Upcoming Deadline
10wFinnhub
ImmunityBio Stock Rises As ANKTIVA Launches in Saudi Arabia
10wBenzinga
ImmunityBio Expands Commercial Access For ANKTIVA Bladder And Lung Cancer Treatment To Saudi Arabia
10wBenzinga